Maintaining equity and reducing risk when prescribing valproate: we still have a way to go
Pract Neurol
.
2023 Feb;23(1):4-5.
doi: 10.1136/pn-2022-003685.
Author
Tony Marson
1
2
Affiliations
1
Pharmacology and Therapeutics, University of Liverpool, Liverpool, Merseyside, UK
[email protected]
.
2
The Walton Centre NHS Foundation Trust, Liverpool, UK.
PMID:
36717205
DOI:
10.1136/pn-2022-003685
No abstract available
Keywords:
ANTICONVULSANTS; EPILEPSY; EVIDENCE-BASED NEUROLOGY.
Publication types
Editorial
MeSH terms
Anticonvulsants / adverse effects
Epilepsy* / drug therapy
Humans
Valproic Acid* / adverse effects
Substances
Valproic Acid
Anticonvulsants